Cowen Maintains Outperform On Sunesis Pharmaceuticals Following Investor Meeting At ASH
In a research report sent to investors, Cowen analyst Eric Schmidt maintained an Outperform rating on Sunesis Pharmaceuticals (NASDAQ:SNSS). No price target was provided.
Schmidt noted, “SNSS hosted an investor meeting at ASH featuring investigators from pivotal VALOR trial in r/r AML. Physicians vouched for vosaroxin’s efficacy, safety and potential approvability despite VALOR having just missed its primary endpoint (p=0.06). An end of Ph. III meeting with the FDA will be in Jan and an EMA filing in H2:15. We think EU approval is likely, though the FDA remains a question mark.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Eric Schmidt has a total average return of 34.6% and a 80.0% success rate. Schmidt has a 58.2% average return when recommending SNSS, and is ranked #42 out of 3401 analysts.